// App-Quantinova.ai

OP0251 (2018) : Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extension

Researchers

Presenter

  • E. Morand

Principal Investigators

  • J.T. Merrill

  • D.A. Isenberg

  • A.H. Kao

  • C. Vazquez–Mateo

  • S. Wax

  • P. Chang

  • K. Pudota

  • C. Aranow

  • D. Wallace

Medical Centers

  • Deakin University, Melbourne, Australia

  • Oklahoma Medical Research Foundation, Oklahoma city, OK.

  • University College London, London, UK

  • EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA

  • Feinstein Institute for Medical Research, Manhasset, NY

  • Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

Locations

  • Australia

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • AstraZeneca and MedImmune

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved